Is TScan Therapeutics, Inc. (TCRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 153.2% / 30% | 456.5% / 30% | 0.0% / 30% | 428.44% / 5% | ✗ NOT HALAL |
| DJIM | 153.2% / 33% | 456.5% / 33% | 0.0% / 33% | 428.44% / 5% | ✗ NOT HALAL |
| MSCI | 26.2% / 33% | 78.2% / 33% | 0.0% / 33% | 428.44% / 5% | ✗ NOT HALAL |
| S&P | 153.2% / 33% | 456.5% / 33% | 0.0% / 33% | 428.44% / 5% | ✗ NOT HALAL |
| FTSE | 26.2% / 33% | 78.2% / 33% | 0.0% / 50% | 428.44% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -851.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -71.3% | |
| Return on Assets (ROA) | -27.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$135M |
| Free Cash Flow | -$140M |
| Total Debt | $94M |
| Debt-to-Equity | 76.5 |
| Current Ratio | 8.4 |
| Total Assets | $229M |
Price & Trading
| Last Close | $1.03 |
| 50-Day MA | $1.06 |
| 200-Day MA | $1.44 |
| Avg Volume | 556K |
| Beta | 1.0 |
|
52-Week Range
$0.88
| |
About TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is TScan Therapeutics, Inc. (TCRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), TScan Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is TScan Therapeutics, Inc.'s debt ratio?
TScan Therapeutics, Inc.'s debt ratio is 153.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 26.2%.
What are TScan Therapeutics, Inc.'s key financial metrics?
TScan Therapeutics, Inc. has a market capitalization of $56M, and revenue of $10M. Return on equity stands at -71.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.